Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Purine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4A | O75164 | 1/20 | 0.36 |
| ▸ | KDM4B | O94953 | 1/20 | 0.36 |
| ▸ | KDM5C | P41229 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.36 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.36 |
| ▸ | FDPS | P14324 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | HBB | P68871 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Purine SCHEMBL5989426 | 1.00 | KDM4A (0.36) | KDM4AKDM4BKDM5CKDM4CKDM5B | |
| Purine SCHEMBL2676957 | 0.95 | KDM4A (0.35) | KDM4AKDM4BKDM5CKDM4CKDM5B | |
| Purine SCHEMBL28270 | 0.93 | KDM4A (0.34) | KDM4AKDM4BKDM5CKDM4CKDM5B | |
| Purine SCHEMBL6421376 | 0.88 | KDM4A (0.38) | KDM4AKDM4BKDM5CKDM4CKDM5B | |
| Purine SCHEMBL3157 | 0.88 | — | — | |
| Purine SCHEMBL2120547 | 0.88 | KDM4A (0.38) | KDM4AKDM4BKDM5CKDM4CKDM5B | |
| Purine SCHEMBL9104228 | 0.88 | FDPS (0.30) | FDPS | |
| Purine SCHEMBL9103866 | 0.88 | FDPS (0.30) | FDPS | |
| Purine SCHEMBL311318 | 0.86 | KDM4A (0.37) | KDM4AKDM4BKDM5CKDM4CKDM5B | |
| Purine SCHEMBL7787135 | 0.86 | KDM4A (0.37) | KDM4AKDM4BKDM5CKDM4CKDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2812441-A1 | NUCLEIC ACID LIGATION METHOD | Wisconsin Alumni Research Foundation (US) | 2014-12-17 | — | — | EP | claimed |
| WO-2013119690-A1 | NUCLEIC ACID LIGATION METHOD | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-08-15 | — | — | WO | claimed |
| US-20130203635-A1 | NUCLEIC ACID LIGATION METHOD | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2013-08-08 | — | — | US | claimed |
| US-20230346827-A1 | TREATMENT OF CORONAVIRUS INFECTIONS | TX MEDIC AB (SE) | 2023-11-02 | — | — | US | disclosed |
| EP-4135719-A1 | TREATMENT OF CORONAVIRUS INFECTIONS | TX Medic AB (SE) | 2023-02-22 | — | — | EP | disclosed |
| CN-108472371-B | EGFR antibody-drug conjugate and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2022-05-24 | — | — | CN | disclosed |
| WO-2021211043-A1 | TREATMENT OF CORONAVIRUS INFECTIONS | TX MEDIC AB (SE) | 2021-10-21 | — | — | WO | disclosed |
| US-10894946-B2 | Multiloop engineered heart muscle tissue | TISSUE SYSTEMS HOLDING GMBH (DE) | 2021-01-19 | — | — | US | disclosed |
| US-20200140820-A1 | MULTILOOP ENGINEERED HEART MUSCLE TISSUE | UNIVERSITATSKLINIKUM HAMBURG-EPPENDORF (DE) | 2020-05-07 | — | — | US | disclosed |
| US-10494605-B2 | Multiloop engineered heart muscle tissue | TISSUE SYSTEMS HOLDING GMBH (DE) | 2019-12-03 | — | — | US | disclosed |
| CN-107653330-A | A kind of multiple PCR reagent kit and its discrimination method of quick discriminating On Planthopperss | 中国水稻研究所 | 2018-02-02 | — | — | CN | disclosed |
| CN-1229413-A | Insecticidal protein toxins from xenorhabdus | DOW AGROSCIENCES LLC (US) | 1999-09-22 | — | — | CN | disclosed |
| EP-0772440-A4 | CARBON MONOXIDE DEPENDENT GUANYLYL CYCLASE MODIFIERS | GLASKY ALVIN J (US) | 1999-05-19 | — | — | EP | disclosed |
| WO-1998045313-A1 | NOVEL UNCOUPLING PROTEIN AND METHODS OF USE | AMYLIN PHARMACEUTICALS, INC. (US) | 1998-10-15 | — | — | WO | disclosed |
| WO-1998042869-A1 | MAMMALIAN DNA PRIMASE SCREENS AND ACTIVITY MODULATING AGENTS | GERON CORPORATION (US) | 1998-10-01 | — | — | WO | disclosed |
| US-5801184-A | Carbon monoxide dependent guanylyl cyclase modifiers and methods of use | SPECTRUM PHARMACEUTICALS, INC. | 1998-09-01 | — | — | US | disclosed |
| EP-0772440-A1 | CARBON MONOXIDE DEPENDENT GUANYLYL CYCLASE MODIFIERS | GLASKY, Alvin J. (US) | 1997-05-14 | — | — | EP | disclosed |
| WO-1996006621-A1 | METAL COMPLEX CONTAINING OLIGONUCLEOSIDE CLEAVAGE COMPOUNDS AND THERAPIES | GENTA INCORPORATED (US) | 1996-03-07 | — | — | WO | disclosed |
| WO-1996003125-A1 | CARBON MONOXIDE DEPENDENT GUANYLYL CYCLASE MODIFIERS | GLASKY ALVIN J (US) | 1996-02-08 | — | — | WO | disclosed |
| US-5447939-A | Purine derivatives used for long term modification of neural activity in mammals, for treatment of mammalian neurological diseases, and for inducing long term changes in membrane potential of mammalian neuron | SPECTRUM PHARMACEUTICALS, INC. | 1995-09-05 | — | — | US | disclosed |